Cormedix Analyst Ratings
Cormedix Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 365.12% | JMP Securities | → $19 | Reiterates | Market Outperform → Market Outperform |
| 08/10/2023 | 46.88% | RBC Capital | → $6 | Initiates Coverage On | → Outperform |
| 08/08/2023 | 193.76% | Needham | $13 → $12 | Maintains | Buy |
| 06/21/2023 | 218.24% | Needham | → $13 | Reiterates | Buy → Buy |
| 05/19/2023 | 365.12% | JMP Securities | $16 → $19 | Maintains | Market Outperform |
| 05/16/2023 | 218.24% | Needham | → $13 | Reiterates | Buy → Buy |
| 03/31/2023 | 291.68% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 03/31/2023 | 218.24% | Needham | → $13 | Reiterates | → Buy |
| 03/03/2023 | 218.24% | Needham | → $13 | Reiterates | → Buy |
| 03/01/2023 | 291.68% | JMP Securities | $14 → $16 | Maintains | Market Perform |
| 11/11/2022 | 218.24% | Needham | $12 → $13 | Maintains | Buy |
| 08/12/2022 | 291.68% | Truist Securities | $27 → $16 | Maintains | Buy |
| 08/09/2022 | 242.72% | JMP Securities | $19 → $14 | Maintains | Market Outperform |
| 08/09/2022 | 193.76% | Needham | $20 → $12 | Maintains | Buy |
| 05/14/2021 | 609.91% | Needham | $31 → $29 | Maintains | Buy |
| 02/17/2021 | 658.87% | Needham | → $31 | Initiates Coverage On | → Buy |
| 02/02/2021 | 756.79% | Truist Securities | $20 → $35 | Maintains | Buy |
| 09/29/2020 | 438.56% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 09/21/2020 | 389.6% | Truist Securities | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 144.8% | HC Wainwright & Co. | $14 → $10 | Maintains | Buy |
| 05/12/2020 | 193.76% | B. Riley Securities | $10 → $12 | Maintains | Buy |
| 03/18/2020 | 144.8% | B. Riley Securities | $15 → $10 | Maintains | Buy |
| 12/18/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 365.12% | JMP 證券 | → 19 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 08/10/2023 | 46.88% | 加拿大皇家銀行資本 | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/08/2023 | 193.76% | 尼德姆 | 13 美元 → 12 美元 | 維護 | 買 |
| 06/21/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | 購買 → 購買 |
| 05/19/2023 | 365.12% | JMP 證券 | 16 美元 → 19 美元 | 維護 | 市場表現跑贏大盤 |
| 05/16/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | 購買 → 購買 |
| 03/31/2023 | 291.68% | JMP 證券 | → 16 美元 | 重申 | → 市場跑贏大盤 |
| 03/31/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | → 購買 |
| 03/03/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | → 購買 |
| 03/01/2023 | 291.68% | JMP 證券 | 14 美元 → 16 美元 | 維護 | 市場表現 |
| 11/11/2022 | 218.24% | 尼德姆 | 12 美元 → 13 美元 | 維護 | 買 |
| 2022 年 12 月 8 日 | 291.68% | Truist 證券 | 27 美元 → 16 美元 | 維護 | 買 |
| 08/09/2022 | 242.72% | JMP 證券 | 19 美元 → 14 美元 | 維護 | 市場表現跑贏大盤 |
| 08/09/2022 | 193.76% | 尼德姆 | 20 美元 → 12 美元 | 維護 | 買 |
| 05/14/2021 | 609.91% | 尼德姆 | 31 美元 → 29 美元 | 維護 | 買 |
| 02/17/2021 | 658.87% | 尼德姆 | → 31 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/02/2021 | 756.79% | Truist 證券 | 20 美元 → 35 美元 | 維護 | 買 |
| 09/29/2020 | 438.56% | JMP 證券 | → 22 美元 | 啓動覆蓋範圍開啓 | → 市場跑贏大盤 |
| 2020 年 9 月 21 日 | 389.6% | Truist 證券 | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/11/2020 | 144.8% | HC Wainwright & Co. | 14 美元 → 10 美元 | 維護 | 買 |
| 05/12/2020 | 193.76% | B. 萊利證券 | 10 美元 → 12 美元 | 維護 | 買 |
| 2020 年 3 月 18 日 | 144.8% | B. 萊利證券 | 15 美元 → 10 美元 | 維護 | 買 |
| 12/18/2019 | — | B. 萊利證券 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Cormedix (CRMD)?
Cormedix (CRMD) 的目標價格是多少？
The latest price target for Cormedix (NASDAQ: CRMD) was reported by JMP Securities on November 15, 2023. The analyst firm set a price target for $19.00 expecting CRMD to rise to within 12 months (a possible 365.12% upside). 10 analyst firms have reported ratings in the last year.
JMP Securities於2023年11月15日公佈了Cormedix（納斯達克股票代碼：CRMD）的最新目標股價。該分析公司將目標股價定爲19.00美元，預計CRMD將在12個月內升至12個月內（可能上漲365.12％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Cormedix (CRMD)?
分析師對Cormedix (CRMD) 的最新評級是多少？
The latest analyst rating for Cormedix (NASDAQ: CRMD) was provided by JMP Securities, and Cormedix reiterated their market outperform rating.
JMP Securities提供了Cormedix（納斯達克股票代碼：CRMD）的最新分析師評級，Cormedix重申了其市場跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Cormedix (CRMD)?
Cormedix (CRMD) 的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cormedix的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Cormedix的最新評級是在2023年11月15日發佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Cormedix (CRMD) correct?
分析師對 Cormedix (CRMD) 的評級正確嗎？
While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a reiterated with a price target of $0.00 to $19.00. The current price Cormedix (CRMD) is trading at is $4.09, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Cormedix（CRMD）評級，目標股價爲0.00美元至19.00美元。Cormedix（CRMD）目前的交易價格爲4.09美元，在分析師的預測區間內。